In 2020 the revision of ICHE9 has become effective in the ICH regions.
Beyond the immediate operational consequences in terms of study documentation development, it has become clearer and clearer that the introduction of the Estimand framework may require methodological solutions which were not common practice in drug development when the revised guidance was released.
In this context, causal inference, or the problem of causality in general, has received a lot of attention in recent years. It appears to provide a suitable methodological framework for tackling some of these challenges.
Five years after its edition dedicated to Estimands, the European Statistical Forum returns to this topic intending to understand the deeper implications of the introduction of the ICHE9 (R1) guidance in terms of how the traditional approach of statistical inference may be affected in its fundamentals of sample size, testing, and estimation by the arrival of causal inference.
The conference will focus, among others, on the following areas:
- Regulatory perspective on study design development based on causal inference methods
- Operational implementation of causal inference methods
- Novel approaches based on causal inference methodologies
- Real case studies and practical approaches
Jens-Otto Andreas - Project Lead Statistician at UCB Biosciences GmbH
Lisa Comarella - Director Biostatistics at CROS NT
Giacomo Mordenti - Head of Biostatistics & Data Management Europe at Daiichi Sankyo Europe GmbH
Marc Vandemeulebroecke - Global Group Head for Dermatology at Novartis Biostatistics
Who should attend?
The conference is addressed to statisticians, pharmacometricians, physicians, regulators, academia and other experts interested in the field belonging to: Pharmaceutical, and Biotechnology companies, CROs, Universities/Hospitals, Academic Research.
We’re working on the programme.
More details available soon
Pre-Conference Training: 15 November 2021 – Online
Stay tuned for the forthcoming updates!
Quote di iscrizione
Registrations will open soon. Stay tuned!